Time to unlock some novel IO targets?
Continuing our latest four part mini-series, this one is on novel targets and agents and we now turn our attention to immuno-oncology in the last two articles pertaining to this particular topic.
You can read the first two articles on targeted therapies here and here.
For the avoidance of any doubt, this latest review is not about T cells, far from it.
Instead we cover six different areas, most of which are related or integrated in some shape of form.
There’s a lot of promising new science now coming out to help us better understand the underlying biology and also think out of the box about ways to enhance or improve on existing research.
To learn more from our oncology coverage and get a heads up on insights emerging our latest analysis and commentary subscribers can log-in or you can click to gain access to BSB Premium Content.
The hurly burly in Chicago between sessions
We have written about the positive and negative effects of various inhibitory checkpoints such as PD-L1, PD-L2, ICOS, and even B7-H3, but there are also other targets within the B7 family that might be worthwhile exploring in the clinic.
Beyond the hullabaloo surrounding the phase 3 anti-PD(L)1 data in 1L NSCLC, there were actually a lot of interesting new and emerging molecules that caught our attention from small biotechs that we plan to highlight throughout the rest of this week. They all have different targets, approaches and rationales, but offer a window into the world of oncology R&D and where things might be headed in the next couple of years.
Today we take a look at one of the long forgotten checkpoint targets and explore a number of aspects that can be considered, given that several companies have preclinical or clinical molecules in early development.
Is this an IO target to watch out for – or not? What are the challenges and opportunities to consider?
It turns out that there could be more than one way to unleash T cells on cancer… as this interview with a company scientist and researcher demonstrates.
To learn more and get a heads up on our latest thought leader interviews and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
Cherry Blossoms and Iwakuni Bridge
We’re continuing our countdown to the 2016 AACR annual meeting in New Orleans with a look at anti TIM-3 and LAG-3 inhibitory checkpoints and highlighting some of the companies with noteworthy abstracts.
In case you missed it, yesterday AACR announced that Vice President Biden will be delivering remarks on the final day of the meeting, Wednesday, April 20th in the “Highlights 2016: Vision for the Future” Plenary Session. As conference diehards, we will be there in person, but AACR have announced they plan to livestream it to the world. It’s a fitting finale to what is set to be a “must attend” meeting for those with an interest in cancer new product development and in particular, cancer immunotherapy.
What can we learn from AACR abstracts on TIM–3 and LAG–3?
There is some early clinical data that we will be checking out (no pun intended) on TIM-3 and LAG-3.
Subscribers can read Day 2 of our “Road to AACR 2016” coverage by logging in, or you can purchase access.